Women with platinum resistant ovarian cancer who have progressed on or after their most recent line of chemotherapy and have received 3 or fewer previous lines of therapy may be eligible to participate in this study. This treatment, which will assess Mirvetuximab Soravtansine (MIRV) verses regular chemotherapy in patients with platinum resistant ovarian cancer, will be led by Dr. Gottfried Konecny and the dynamic research team from the UCLA Department of Obstetrics and Gynecology
Participants must meet the following criteria:
If you've answered yes to all of the above questions, please contact us.
All participants enrolled in the study will undergo screening for participation. Tumor samples will be assessed for FRα expression.
Once in the study, during the 1stvisit, participants will be randomized (like drawing numbers from a hat) to one of the 2 treatment groups. One of the treatment groups will receive MIRV and the other treatment group will receive standard chemotherapy. Your study doctor will discuss with you which of the standard chemotherapy options would be most appropriate for you prior to the randomization process. You will have an equal chance of being assigned to treatment with MIRV or to treatment with a standard chemotherapy option.
UCLA Protocol ID: IRB# 20-000317
Please call (310) 794-9652 or email [email protected] to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.